Last reviewed · How we verify
Topiramate add-on therapy
At a glance
| Generic name | Topiramate add-on therapy |
|---|---|
| Sponsor | Johnson & Johnson Taiwan Ltd |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight (PHASE3)
- Metabolic Surgery for Atrial Fibrillation Elimination (PHASE4)
- Combining a Smartphone App With Medications to Manage Heavy Drinking (NA)
- SMART Use of Medication for the Treatment of Adolescent Severe Obesity (PHASE2)
- Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial) (PHASE3)
- Topiramate in Neonates Receiving Whole Body Cooling for Hypoxic Ischemic Encephalopathy (PHASE1, PHASE2)
- Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study. (PHASE4)
- A Toolbox Approach to Obesity Treatment in Primary Care (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topiramate add-on therapy CI brief — competitive landscape report
- Topiramate add-on therapy updates RSS · CI watch RSS
- Johnson & Johnson Taiwan Ltd portfolio CI